17-Hydroxyprogesterone caproate powder video
I.17-Hydroxyprogesterone caproate powder basic Characters:
|Name:||17-Hydroxyprogesterone caproate powder|
|Storage Temp:||Room Temperature|
|Color:||White to off-white powder|
II. 17-Hydroxyprogesterone caproate powder cycle
Chemical Names: 17-Hydroxyprogesterone caproate powder
Other Names: 17-OHPC, 17P, hexanoate
2. 17-Hydroxyprogesterone caproate powder Usage:
The drug 17-alpha hydroxyprogesterone caproate is an injectable synthetic progestin. It has been proven effective in preventing or delaying preterm birth in singleton pregnancies for women with a history of spontaneous preterm birth.1 Once widely available as an inexpensive compounded drug, it now has a branded version (Makena; AMAG Pharmaceuticals) that costs approximately 100 times more than the original. On February 4, 2011, KV Pharmaceutical Company (later renamed Lumara) received approval from the US Food and Drug Administration to manufacture and market Makena, which is composed of the same active ingredients as found in the original compounded formulation. The approval included an orphan drug designation and gave KV Pharmaceutical Company the exclusive rights to manufacture Makena, which potentially contributed to its high listed price. For this study, we used an insurance claims database to examine prescriptions for 17-alpha hydroxyprogesterone caproate among nearly 4000 commercially insured (not Medicaid) pregnant women. Our aim was to understand the use, costs, and outcomes of the branded and compounded versions of the drug.
3.What is the dosage of 17-Hydroxyprogesterone caproate powder?
250 mg once weekly (every 7 days); begin therapy between 16 weeks, 0 days and 20 weeks, 6 days of gestation; continue until week 37 (through 36 weeks, 6 days) of gestation or delivery, whichever occurs first.
We conducted a double-blind, placebo-controlled trial involving pregnant women with a documented history of spontaneous preterm delivery. Women were enrolled at 19 clinical centers at 16 to 20 weeks of gestation and randomly assigned by a central data center, in a 2:1 ratio, to receive either weekly injections of 250 mg of 17P or weekly injections of an inert oil placebo; injections were continued until delivery or to 36 weeks of gestation. The primary outcome was preterm delivery before 37 weeks of gestation. Analysis was performed according to the intention-to-treat principle.
Base-line characteristics of the 310 women in the progesterone group and the 153 women in the placebo group were similar. Treatment with 17P significantly reduced the risk of delivery at less than 37 weeks of gestation (incidence, 36.3 percent in the progesterone group vs. 54.9 percent in the placebo group; relative risk, 0.66 [95 percent confidence interval, 0.54 to 0.81]), delivery at less than 35 weeks of gestation (incidence, 20.6 percent vs. 30.7 percent; relative risk, 0.67 [95 percent confidence interval, 0.48 to 0.93]), and delivery at less than 32 weeks of gestation (11.4 percent vs. 19.6 percent; relative risk, 0.58 [95 percent confidence interval, 0.37 to 0.91]). Infants of women treated with 17P had significantly lower rates of necrotizing enterocolitis, intraventricular hemorrhage, and need for supplemental oxygen.
Weekly injections of 17P resulted in a substantial reduction in the rate of recurrent preterm delivery among women who were at particularly high risk for preterm delivery and reduced the likelihood of several complications in their infants.
4.How Cortexolone 17-Hydroxyprogesterone caproate powder works?
17α-hydroxyprogesterone caproate (17-OHPC) is a synthetic progestogen. The human body does not make the caproate molecule. Another name for caproate is “hexanoate,” which is an ester derived from hexanoic (or caproic) acid. The formula of 17-OHPC is displayed in the Figure. Some physicians have stated that 17-OHPC is found in goats. This seems to be a folktale, because the identification of this molecule from natural body fluids, tissues from goats, or any other living organism could not be confirmed in a literature search.
The effect of 17-OHPC on cervical length in patients with a history of ≥ 1 preterm births who were allocated to receive 17-OHPC vs an untreated control group. No difference in cervical length measurements over time was observed in women who received 17-OHPC. In contrast, vaginal progesterone reduced the rate of cervical shortening in patients with a history of preterm birth or premature cervical shortening.
17 alpha-hydroxyprogesterone caproate (17P) is a synthetic form of progesterone that has been shown to reduce the recurrence of PTB for women with singleton gestations that have a history of previous. Women with a previous history of PTB are more likely to have another preterm infant compared to women who have not. Commonly prescribed by doctors, 17P is administered through weekly injections beginning at 16-24 weeks until delivery. Studies show that administering 17P to an eligible woman reduces the chance of having another PTB by 33 percent. Each year, approximately, 30,000 pregnant women meet the qualification and are considered eligible for 17P.
Reduction of risk of preterm birth in women with a singleton pregnancy having a history of singleton spontaneous preterm birth (designated an orphan drug by FDA for this use).
Efficacy determined based on improvement in proportion of women who delivered at <37 weeks of gestation; direct clinical benefit (e.g., improvement in neonatal morbidity and mortality) not established.
Safety and efficacy demonstrated only in women with a prior spontaneous singleton birth; not intended for use in women with multiple gestations or other risk factors for preterm birth.
ACOG recommends offering progesterone supplementation for prevention of recurrent preterm birth to women with a singleton pregnancy and a prior spontaneous preterm birth at <37 weeks of gestation due to spontaneous preterm labor or premature rupture of membranes.
6.17-Hydroxyprogesterone caproate powder:
Min order 10grams.
The inquiry on normal quantity(Within 1kg) can be sent out in 12 hours after payment.
For larger order can be sent out in 3 working days after payment.
7.17-Hydroxyprogesterone caproate powder Recipes:
To inquiry our Customer Representitive(CSR) for details, for your reference.
8.17-Hydroxyprogesterone caproate powder Marketing:
To be provided in the coming future.
9.Does 17-Hydroxyprogesterone caproate powder Have Any Side Effects?
- Synthetic progestin; produced by esterification of 17α-hydroxyprogesterone, a naturally occurring metabolite of progesterone, with caproic acid.
- Has strong progestogenic activity; appears to produce a longer lasting and more potent progestational effect on endometrium than progesterone.
- Does not appear to have androgenic, antiandrogenic, estrogenic, or glucocorticoid activity.
Mechanism of action in reducing the risk of recurrent preterm birth not known
III. 17-Hydroxyprogesterone caproate powder HNMR
IV. How to buy 17-Hydroxyprogesterone caproate powder from AASraw?
1.To contact us by our email inquiry system,or online skypecustomer service representative(CSR).
2.To provide us your inquired quantity and address.
3.Our CSR will provide you the quotation, payment term, tracking number, delivery ways and estimated arrival date(ETA).
4.Payment done and the goods will be sent out in 12 hours(For order within 10kg).
5.Goods received and give comments.
PRECAUTION AND DISCLAIMER:
This Material is Sold For Research Use Only. Terms of Sale Apply. Not for Human Consumption, nor Medical, Veterinary, or Household Uses.